[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nephrotic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nephrotic-syndrome":631},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,51,64,108,137,160,186,213,233,265,289,320,341,360,385,411,430,452,479,500,519,539,557,583,610],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100054144",false,"NCT07313787","Effects of Meal Macronutrients on Postprandial Lipids","Prospective Cross-Over Study of the Effects of Meal Macronutrients on Postprandial Lipids","* INCLUSION CRITERIA:\n\nCommon inclusion criteria (all groups):\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Age \\>= 18 years\n2. Average alcohol intake in the past 6 months \\\u003C 3 drinks (approximately 30g) per day (male) or \\\u003C 2 drinks (approximately 20 g) per day (female)\n\nHealthy control specific inclusion criteria:\n\n1. In good general health with no known active medical conditions as evidenced by medical history\n2. Fasting glucose \\\u003C100 mg\u002FdL\n3. HbA1c \\\u003C5.7%\n4. Fasting triglycerides \\\u003C150 mg\u002FdL\n5. ALT and AST within normal limits\n6. BMI \\>=18.5 to \\\u003C25 kg\u002Fm\\^2 (or \\\u003C23 kg\u002Fm\\^2 in participants of Asian descent)\n7. Not taking any medications or supplements that, in the opinion of the investigator, would interfere with interpretation of study data.\n\nMetabolic syndrome specific inclusion criteria\n\n1\\. Obesity defined as either\n\n1. BMI \\>30 kg\u002Fm\\^2 (or \\>=27 kg\u002Fm\\^2 in participants of Asian descent), OR\n2. Elevated waist circumference as defined below:\n\n   * Country\u002FEthnic group - Europid, Sub-Saharan African, Eastern Mediterranean and Middle East (Arab):\n\n     --Sex: Male - Waist circumference: \\>=94cm\n\n     --Sex: Female - Waist circumference: \\>=80cm\n   * Country\u002FEthnic group - South Asian, Chinese, Japanese, Ethnic South and Central American:\n\n     * Sex: Male - Waist circumference: \\>=90cm\n     * Sex: Female - Waist circumference: \\>=80cm\n\n       2\\. Elevated triglycerides defined as EITHER\n\n       2a. Fasting triglycerides \\>= 150 mg\u002FdL at screening, OR\n\n       2b. Specific treatment for hypertriglyceridemia\n\n       3\\. Low HDL cholesterol, defined as EITHER\n\n       3a. HDL \\\u003C40 mg\u002FdL (males) or \\\u003C50 mg\u002FdL (females) at screening, OR\n\n       3b. Specific treatment for low HDL\n\n       4\\. Elevated blood pressure defined as EITHER\n\n       4a. Systolic BP \\>= 130 at screening, OR\n\n       4b. Diastolic BP \\>= 85 mm Hg at screening, OR\n\n       4c. Treatment of previously diagnosed hypertension\n\n       5\\. Elevated glucose defined as EITHER\n\n       5a. HbA1c \\>= 5.7% (at screening), OR\n\n       5b. Fasting serum glucose \\>= 100 mg\u002FdL (at screening), OR\n\n       5c. 2-hour post-load glucose levels \\>= 140 mg\u002FdL (by history), OR\n\n       5d. Prior diagnosis of type 2 diabetes\n\n   Lipodystrophy-specific inclusion criteria:\n   1. Clinical diagnosis of generalized or partial lipodystrophy based on reduction in adipose tissue outside the normal range in some or all adipose depots (including, at aminimum, the gluteofemoral depot).\n   2. Insulin resistance as defined by fasting insulin \\>22.5 or high exogenous insulin requirement (\\> 2 units per kg per day or \\> 200 units total per day) at screening.\n\n   Nephrotic syndrome specific inclusion criteria\n   1. History of biopsy proven non-diabetic glomerular disease (any histology)\n   2. Nephrotic range proteinuria defined by ANY of the following:\n\n   2a. Protein\u002Fcreatinine ratio uPCR \\>= 3.5 g\u002Fg at screening, OR\n\n   2b. 24 hour protein excretion \\>= 3.5 gr\u002F24hr) at screening, OR\n\n   2c. History of nephrotic range proteinuria (as defined above) within the past 5 years but in complete (defined as proteinuria \\\u003C= 0.3 g\u002Fday or partial remission (defined as a 50% or greater decrease in proteinuria compared to baseline and proteinuria \\\u003C 3.5 g\u002Fday) based on 24 hr urine or uPCR at time of screening\n\n   EXCLUSION CRITERIA:\n\n   Common exclusion criteria (all groups):\n\n   An individual who meets any of the following criteria will be excluded from participation in this study:\n   1. Consuming extreme macronutrient diet (e.g., very low-carbohydrate, high fat diets such as ketogenic, paleo or Atkins diets, among others).\n   2. Plans to actively gain or lose weight during the study period (other than changes in water balance as clinically needed in subjects with nephrotic syndrome).\n   3. Change in body weight of \\>5% or \\>3 kg (whichever is larger) in the 3 months prior to screening (by participant report) in participants who do NOT have nephrotic syndrome.\n   4. Body weight \\>450 lbs (upper limit that can be accommodated by DXA scanner).\n   5. Participating in a regular strenuous exercise program (\\> 2h\u002Fweek of vigorous activity) as determined by volunteer report or evidence of vigorous exercising in order to lose weight, change body shape, or to counteract the effects of eating.\n   6. Uncontrolled diabetes, defined as HbA1c \\>9% at screening.\n   7. Lipemia defined as fasting or non-fasting triglycerides of \\>1000 mg\u002FdL at screening.\n   8. Renal dysfunction defined as eGFR \\\u003C50 mL\u002Fmin\u002F1.73 m\\^2 at screening.\n   9. In participants with liver disease, history of decompensated advanced liver disease, defined as direct bilirubin \\> 0.5 g\u002FdL, PT \\> 18 seconds, albumin \\\u003C 3 g\u002FdL, MELD score \\> 12, or history of ascites, encephalopathy, variceal bleeding, spontaneous bacterial\n\n      peritonitis or liver transplant.\n   10. History of hypertriglyceridemia-induced pancreatitis within 3 months prior to screening.\n   11. Positive pregnancy test or breastfeeding at screening.\n   12. Clinically significant abnormalities in thyroid function, blood counts, as assessed by screening labs.\n   13. Acute cardiovascular events within the past 6 months\n   14. Anemia (Hgb \\\u003C10 mg\u002FdL in women or \\\u003C12 mg\u002FdL in men) at screening\n   15. Food allergies or other dietary restrictions that could increase risk associated with test meals or cause the subject to be unwilling to consume test meals (i.e. celiac disease, vegan diets).\n   16. Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other known conditions that could affect intestinal fat absorption.\n   17. Subjects treated with tamoxifen, estrogens, or progestins that have not been stable for \\>4 weeks prior to screening.\n   18. Blood donation in the last 2 weeks or planned blood donation during the study\n   19. Subjects requiring regular transfusions for any reason.\n   20. Subjects with known gastroparesis\n   21. Inability to adhere to Lifestyle Considerations throughout study duration.\n   22. Inability of the subject to understand and the unwillingness to sign a written informed consent document.\n   23. Unwillingness to comply with all study procedures and unavailable for the duration of the study\n   24. Any other condition or medication which, in the opinion of the investigator, increases risk to the subject, prevents the subject from complying with study procedures, prevents the subject from completing the study, or interferes with the interpretation of study results.","ALL","18 Years","120 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Background:\n\nAbnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome.\n\nObjective:\n\nTo learn more about how different types of foods affect fat levels in the blood.\n\nEligibility:\n\nPeople aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal.\n\nParticipants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after.\n\nParticipants will have other tests during their stays:\n\n* A resting metabolic test captures the air they exhale and measures how much energy they use at rest.\n* A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have.\n* A Fibroscan is a special type of ultrasound of the liver.\n* A body surface scan uses lasers to measure the total area of the body.\n* A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body.\n\nParticipants may opt to have a third visit. At this visit, the breakfast will be high in protein....",[26,27,28,29,30,31],"Nephrotic Syndrome","Lipodystrophy","Metabolic Syndrome","Healthy Volunteer","Diabetes","Metabolic Associated Steatotic Liver Disease",[33,34,35,36,37],"postprandial lipids","macronutrient","CARBOHYDRATES","FATS","Proteins","NOT_YET_RECRUITING","2026-07-10",{"date":41,"type":42},"2026-07-13","ACTUAL",{"date":44,"type":20},"2026-07-16",{"date":46,"type":20},"2031-08-01",{"name":48,"class":49},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":52,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":24,"conditions":55,"keywords":56,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":63,"locationsCount":50},"100617066",{"count":19,"type":20},[23],[26,27,28,29,30,31],[33,34,35,36,37],"2026-07-01",{"date":59,"type":42},"2026-07-02",{"date":61,"type":20},"2026-07-07",{"date":46,"type":20},{"name":48,"class":49},{"id":65,"slug":4,"hasResults":10,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":10,"sex":15,"minAge":70,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":80,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":50},"100591638","NCT06983028","Atacicept in Multiple Glomerular Diseases","A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)","Inclusion Criteria:\n\n* Weight of at least 40 kg\n* On a stable prescribed standard of care (SoC) treatment regimen according to local guidelines and the specific requirements for each disease\n* Systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤90 mmHg at Screening.\n\nDiagnosis of IgAN, IgAVN, pMN, MCD, FSGS, or primary nephrotic syndrome\n\nFor patients enrolling in IgAN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy proven IgAN, IgAVN, or recurrent IgAN in kidney transplant\n* UPCR ≥ 0.5 g\u002Fg or UPE ≥ 0.5 g\u002Fday on 24h urine\n* eGFR≥ 20 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pediatric IgAN Cohorts (eligibility varies by cohort):\n\n* Age ≥ 2 years and \\\u003C 18 years\n* Biopsy proven IgAN or IgAVN\n* On stable prescribed regimen of RAASi (or SoC) for at least 8 weeks\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* eGFR≥ 30 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pMN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy-proven pMN\n* Anti PLA2R antibodies ≥ 25 RU\u002FmL\n* UPCR ≥ 1.5 g\u002Fg or UPE ≥ 1.5 g\u002Fd on 24h urine\n* At low risk for spontaneous remission (based on severity or duration of disease)\n\nFor patients enrolling in Nephrotic Syndrome cohorts (MCD, FSGS, or pediatric idiopathic nephrotic syndrome):\n\n* Age ≥ 10 years\n* eGFR ≥30 mL\u002Fmin\u002F1.73m2\n* Adults with biopsy diagnosis of primary MCD or FSGS (adults) or children with challenging clinical course with steroids (frequenlty relapsing, steroid-dependent, or steroid-resistant)\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* Evidence of anti-nephrin antibodies\n\nKey Exclusion Criteria:\n\n* Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR) within 12 weeks prior to and at Screening)\n* Active viral or bacterial infections\n* Existing conditions or clinically significant laboratory abnormalities that may interfere with participation in this study\n* Administration of live and live-attenuated vaccinations within 30 days prior to enrollment\n* Immunosuppressant medications within 4 weeks prior to dosing with atacicept (except transplant maintenance immunosuppression).\n* Known hypersensitivity to atacicept or any component of the formulated atacicept\n* Additional criteria apply to each cohort\u002Fdisease.","2 Years",{"count":72,"type":20},250,[23],"A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.",[76,77,26,78,79],"pMN","IgAN","MCD","FSGS",[81,82,83,84,85,86,26,87,88,89,90,91,92,93,94,95,96],"IGA Glomerulonephritis","IGA Nephropathy","Iga Nephropathy 1","Immunoglobulin A Nephropathy Nephritis","IGA Type Nephropathy, IGA","Primary Membranous Nephropathy","Immunoglobulin A (IgA)","Immunoglobulin A vasculitis with nephritis (IgAVN)","Anti-PLA2R associated membranous nephropathy (PLA2R-MN)","Idiopathic\u002Fprimary nephrotic syndrome (MCD\u002FFSGS)","Glomerulonephritis","Nephritis","Autoimmune Diseases","Immune System Diseases","Kidney Diseases","Glomerulonephritis, IGA","RECRUITING","2026-06-23",{"date":100,"type":42},"2026-06-26",{"date":102,"type":42},"2025-07-07",{"date":104,"type":20},"2027-11",{"name":106,"class":107},"Vera Therapeutics, Inc.","INDUSTRY",{"id":109,"slug":4,"hasResults":10,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100358652","NCT03949855","Belimumab With Rituximab for Primary Membranous Nephropathy","Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)","REBOOT","Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be eligible for this study-\n\n1. Age 18 to 75 years inclusive\n2. Diagnosis of one of the following:\n\n   1. Primary MN confirmed by a kidney biopsy within the past 5 years\n   2. Primary MN that is relapsing following a CR (Section 3.3.1) or PR (Section 3.3.2), confirmed by a kidney biopsy within the past 7 years\n   3. Nephrotic syndrome with eGFR \\> 60 mL\u002Fmin\u002F1.73m2 and no history of immunosuppressant treatment (e.g. glucocorticoids, cyclophosphamide, cyclosporine A, tacrolimus, B-cell depleting agent) for nephrotic syndrome, and without evidence of a secondary cause of nephrotic syndrome\n   4. Nephrotic syndrome and a contraindication to kidney biopsy (e.g., anticoagulation, solitary kidney, body habitus that increases the risk of biopsy, or other contraindication in the opinion of the investigator), and without evidence of a secondary cause of nephrotic syndrome\n3. Serum anti-PLA2R positive\n4. eGFR ≥ 30 mL\u002Fmin\u002F1.73m2 while on maximally tolerated RAS blockade\n5. Proteinuria:\n\n   1. ≥ 4 and \\\u003C 8 g\u002Fday that has persisted for at least the previous 3 months while on maximally tolerated RAS blockade. Documentation of persistent proteinuria may be from a 24-hour collection or calculated from a spot urine collection. Or,\n   2. ≥ 8 g\u002Fday while on maximally tolerated RAS blockade\n6. Blood pressure while on maximally tolerated RAS blockade:\n\n   1. Systolic blood pressure ≤ 140 mmHg\n   2. Diastolic blood pressure ≤ 90 mmHg\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will not be eligible for this study-\n\n1. Secondary cause of MN (e.g., SLE, drug, infection, malignancy) suggested by review of the patient's medical history and\u002For clinical presentation\n2. Rituximab use within the previous 12 months\n3. Rituximab use \\> 12 months ago:\n\n   1. With an undetectable CD19 B cell count, or\n   2. Did not result in a CR (Section 3.3.1) or PR (Section 3.3.2) with rituximab treatment alone (e.g., without other immunosuppressive or immunomodulatory therapy)\n4. Use of anti-B cell therapy other than rituximab within the previous 12 months (or 5 half-lives, whichever is greater)\n5. Cyclophosphamide use within the past 3 months\n6. Use of other immunosuppressive medications such as cyclosporine or tacrolimus within the past 30 days\n7. Use of systemic corticosteroids within the past 30 days\n8. Use of any biologic investigational agent (defined as any drug not approved for sale in the country it is used) in the previous 12 months\n9. Use of any non-biologic investigational agent in the past 30 days (or 5 half-lives, whichever is greater)\n10. Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) ≥ 9.0%\n11. Patients with diabetic glomerulopathy on renal biopsy that is:\n\n    1. Greater than Class I diabetic glomerulopathy, or\n    2. Class I diabetic glomerulopathy with a history of poor diabetic control (e.g., HbA1c ≥ 9.0%) since time of biopsy\n12. Unstable kidney function defined as \\> 20% decrease in eGFR during the previous 3 months due to primary MN, as determined by the site investigator in consultation with the protocol chair\n13. Decrease in proteinuria by 50% or more during the previous 12 months\n14. WBC count \\\u003C 3.0 x 103\u002Fμl\n15. Absolute neutrophil count \\\u003C 1.5 x 103\u002Fμl\n16. Moderately severe anemia (hemoglobin \\\u003C 9 g\u002FdL)\n17. History of primary immunodeficiency\n18. Serum IgA \\\u003C 10 mg\u002FdL\n19. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2x the upper limit of normal (ULN)\n20. Positive HIV serology\n21. Positive HCV serology, unless treated with anti-viral therapy with achievement of a sustained virologic response (undetectable viral load 24 weeks after cessation of therapy)\n22. Evidence of current or prior infection with hepatitis B, as indicated by positive HBsAg or positive HBcAb\n23. Positive QuantiFERON - TB Gold test results. PPD tuberculin test may be substituted for QuantiFERON - TB Gold test\n24. History of lung disease with FVC \\\u003C 70% predicted, DLCO \\\u003C 70% predicted, or requiring supplemental oxygen\n25. History of malignant neoplasm within the last 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years\n26. Absence of individualized, age-appropriate cancer screening\n27. Women of child-bearing potential who are pregnant, nursing, or unwilling to be sexually inactive or use FDA-approved contraception until week 104\n28. Acute or chronic infection, including current use of suppressive therapy for chronic infection, hospitalization for treatment of infection in the past 60 days, or parenteral anti-microbial (including anti-bacterial, anti-viral, or anti-fungal agents) use in the past 60 days for infection\n29. History of an anaphylactic reaction or known sensitivity or intolerance to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies, including rituximab or belimumab\n30. Evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and\u002For any suicidal ideation in the last 2 months, or who in the investigator's judgment, poses a significant suicide risk\n31. Evidence of current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence in the past 12 months\n32. Vaccination with a live vaccine within the past 30 days\n33. Other diseases or conditions or other clinically significant abnormal laboratory value which in the opinion of the investigator would put the patient at risk or confound the results of the study\n34. Inability to comply with study and follow-up procedures","75 Years",{"count":117,"type":20},58,[23],"The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy.\n\nBackground:\n\nPrimary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life.\n\nPrimary MN is recognized to be an autoimmune disease, a disease where the body's own immune system causes damage to kidneys. This damage can cause the loss of too much protein in the urine.\n\nDrugs used to treat MN aim to reduce the attack by one's own immune system on the kidneys by blocking inflammation and reducing the immune system's function. These drugs can have serious side effects and often do not cure the disease. There is a need for new treatments for MN that are better at improving the disease while reducing fewer treatment associated side effects.\n\nIn this study, researchers will evaluate if treatment with a combination of two different drugs, belimumab and rituximab, is effective at blocking the immune attacks on the kidney compared to rituximab alone. Rituximab works by decreasing a type of immune cell, called B cells. B cells are known to have a role in MN. Once these cells are removed, disease may become less active or even inactive. However, after stopping treatment, the body will make new B cells which may cause disease to become active again.\n\nBelimumab works by decreasing the new B cells produced by the body and, may even change the type of new B cells subsequently produced. Belimumab is approved by the US Food and Drug Administration (FDA) to treat systemic lupus erythematosus (also referred to as lupus or SLE). Rituximab is approved by the FDA to treat some types of cancer, rheumatoid arthritis, and vasculitis. Neither rituximab nor belimumab is approved by the FDA to treat MN. Treatment with a combination of belimumab and rituximab has not been studied in individuals with MN, but has been tested in other autoimmune diseases, including lupus nephritis and Sjögren's syndrome.",[121,26],"Membranous Nephropathy",[86,123,124,125,126],"nephrotic syndrome","Pharmacokinetics (PK) Analysis","Double-Blind (Masked), Placebo-Controlled Clinical Trial","Co-administered belimumab and rituximab","2026-06-22",{"date":129,"type":42},"2026-06-24",{"date":131,"type":42},"2020-03-06",{"date":133,"type":20},"2030-03-01",{"name":135,"class":49},"National Institute of Allergy and Infectious Diseases (NIAID)",20,{"id":138,"slug":4,"hasResults":10,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":10,"sex":15,"minAge":144,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":159},"100375865","NCT04174066","From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With MGLS and HSFP","From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With Minimal Glomerular Injury Nephrotic Syndrome (MGLS) and Primary Segmental and Focal Hyalinosis (HSFP)","BiobankSNI","Inclusion Criteria:\n\n* First episode of idiopathic nephrotic syndrome in a child aged 12 months to 18 years with a weight \\> 10 kg and biologically defined as proteinuria \\> 0.20 g \u002F mmol creatinuria and hypoalbuminemia \\\u003C25 g \u002F mmol\n* First episode of NIS defined in adults as albumin level \\\u003C30 g \u002F L and a urinary protein\u002Fcreatinine ratio (UPCR) ≥ 300 mg \u002F mmol systematically associated with the performance of a renal anatomopathological examination and characterized by the absence of identifiable lesions by light microscopy (SNLGM) or the presence of HSF lesions.\n* For adults: signed informed consent to participate in the study\n* For children: patients will be informed and a written informed consent form will be signed by both parents of the children at inclusion\n* Patients affiliated to the French health system\n\nExclusion Criteria:\n\n* Patients who have previously received corticosteroids and\u002For immunosuppressants\n* Patients with reduced CH50 and\u002For low C3 and\u002For low C4 and\u002For low C4 (in some cases increased sC5b9 and\u002For presence of a C3 nephritic Factor; an anti-C3b...)\n* SNLGM resulting from a secondary process (lymphoid hematopathies or neoplasia) or occurring following the administration of a treatment known to be associated with an SNLGM (lithium, interferon, non-steroidal anti-inflammatory drugs)\n* Non-primary FHH (absence of Nephrotic Syndrome, etiological assessment revealing FHH secondary to an identified cause (genetic or not), no introduction of corticosteroids or immunosuppressants as first-line treatment)\n* Positive serological screening test for HIV, hepatitis B or C\n* Positive immunological tests for antinuclear and anti-DNA antibodies or anti-PLA2R1 and anti-THSD7A\n* Patient under guardianship or curatorship","12 Months",{"count":146,"type":20},144,"OBSERVATIONAL","Idiopathic Nephrotic Syndrome (INS) is a kidney disease characterized by massive proteinuria and hypoalbuminemia. It includes two anatomopathological entities: nephrotic syndrome with minimal glomerular lesions (SNLGM) and primary segmental and focal hyalinosis (PHF). Renal biopsy reveals a fusion of the feet of the podocytes without inflammatory lesions or deposits of immune complexes. Clinical and experimental observations strongly suggest that the immune system and podocyte dysfunction are the two facets of the disease. There are currently no clinical or biological markers to predict the diagnosis of corticosteroid sensitivity, corticosteroid dependence, or risk of recurrence of kidney disease after kidney transplantation. To our knowledge, no prospective studies have been designed to study both immune system alterations and podocyte damage as well as genetic predisposition variants in NIS. Therefore, the use of steroids\u002Fimmunosuppressive agents is purely empirical with a multitude of side effects.\n\nThe objective is to identify and test new therapeutic targets rather than conducting new trials with existing treatments, using either drug candidates or molecules selected by high throughput screening of libraries of repositioning molecules using an appropriate read-out. The biobank may also be used to analyze the effects of conventional treatments on identified new biomarkers. We expect the project to produce original and patentable results with subsequent valuation. Patentability will be anticipated before any publication on the subject. The patent and valorization cells of hospitals, INSERM and Universities will be involved in the results as soon as they are obtained.",[26],"2026-06-18",{"date":127,"type":42},{"date":153,"type":42},"2020-05-20",{"date":155,"type":20},"2031-05-20",{"name":157,"class":158},"Centre Hospitalier Universitaire de Nice","OTHER",2,{"id":161,"slug":4,"hasResults":10,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":159},"100131289","NCT00977977","Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study\n2. Male or female, \\>= 18 years of age\n3. Nephrotic range proteinuria that persists for at least 6 months post diagnosis of membranous nephropathy greater than 3.5 grams \u002F24 hours (based on 24-hour urine collection).\n\n   a. If the subject s renal function rapidly declines in less than 6 months could proceed with immunosuppression therapy sooner such as complications of the nephrotic syndrome that are not controlled with supportive therapy or evidence of decline in glomerular filtration rate or proteinuria \\>8 grams\u002Fday. Subjects with declining renal function and\u002For high-grade proteinuria due to MN are considered \"high risk\" subjects and have a higher probability of progression to end stage kidney disease.\n4. Nephrotic range proteinuria (\\>3.5 g\u002F24 hours) that persists despite angiotensin antagonist therapy (ACE inhibitor or ARB) for at least 2 months unless intolerant.\n\n   a. The rationale is that blockade of the renin angiotensin system (RAAS) is widely considered to be part of the standard of care treatment for subjects with the nephrotic syndrome. Nephrotic range proteinuria will be defined as an estimated average proteinuria \\>3.5 g\u002F24 hours in adults based on at least two 24-hour urine protein excretions obtained prior to initiating therapy. Incomplete urine\n\n   collections (based on inadequate creatinine excretion) will be excluded.\n5. Renal biopsy within the past 24 months must reveal typical changes of membranous nephropathy by light and electron microscopy or a positive anti-PLA2R antibody test in the serum. There has been a change in the management strategies for MN such that a renal biopsy is not absolutely required for diagnosis if patient has positive circulating anti-PLA2R antibody.\n\n   a. Based on published KDIGO 2021 Clinical Practice Guidelines 3.1.1 patients with MN who are positive for anti-PLA2R do not require renal biopsy as long as renal function is normal (eGFR \\>60) and has not had immunosuppression as it has been demonstrated that results of the biopsy have not altered clinical approach and management. If not PLA2R positive, renal biopsy within 24 months is still required.\n6. Blood pressure \\\u003C=140\u002F90 on \\>75% of measurement while on anti-hypertensive treatment for at least 1-2 months.\n7. There is no evidence to suggest secondary forms of membranous nephropathy.\n8. Ability to take oral medication and be willing to adhere to the cyclosporine regimen\n9. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for 12 months after the last Rituximab infusion.\n10. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.\n11. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Estimated GFR\\\u003C40 ml\u002Fmin\u002F1.73 m\\^2 from the preceding 2 months prior to enrollment while on ACEI\u002FARB therapy.\n2. Immunosuppressive medications or experimental medications of any type during the three-month period prior to initiating Rituximab and cyclosporine.\n3. Prior exposure to cyclosporine or tacrolimus for more than 6 months and\u002For evidence of intolerance or toxicity associated with cyclosporine treatment of any duration including irreversible azotemia, liver dysfunction or hypertension\n4. Rituximab use within the previous 12 months.\n5. Clinically significant medical conditions (i.e., severe heart failure NYHA class IV, uncontrolled coronary artery disease\u002Funstable angina), which in the opinion of the investigator, could increase the subject s risk of participating in the study or could confound the interpretation of the results of the study.\n6. Positive HIV serology\n7. Positive HCV serology\n8. Active acute or chronic infection requiring antimicrobial therapy or serious viral infection cytomegalovirus, herpes simplex, varicella zoster virus (chicken pox or shingles), Parvovirus B19 (can be based on previous medical records within the past 24-months)\n9. Live viral vaccines within one month prior to Rituximab.\n10. Pregnancy or lactation\n11. Cancer diagnosis or cancer recurrence within the preceding 5 years, excluding basal cell carcinoma of the skin. The rationale is that immunosuppression may accelerate cancer progression.\n12. Clinical evidence of cirrhosis or chronic active liver disease sufficiently severe to impair cyclosporine metabolism; this would include a prolonged prothrombin time.\n13. Cytopenia (neutrophils \\\u003C1500\u002Fmm\\^3 and\u002For thrombocytopenia \\\u003C75,000) and\u002For CD4 T cell count \\\u003C200\u002Fmm\\^3). The rationale is that Rituximab therapy may be followed by cytopenia with the granulocyte lineage being at greatest risk. Patients with low CD4 T cell counts are prone to infection which can be exacerbated by Rituximab.\n14. Diabetes mellitus. The rationale is that diabetes may lead to worsening of proteinuria that would not respond to immunosuppression and would confound the results.","90 Years",{"count":167,"type":20},30,[23],"Background:\n\n* Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste products from the blood. This damage causes leakage of blood proteins into the urine and is associated with low blood protein levels, high blood cholesterol values, and swelling of the legs. These problems can decrease or go away without treatment in about 25 percent of patients, but if they persist, some patients may experience impaired (or loss of) kidney function, blood vessel and heart disease, and a risk of forming blood clots in veins.\n* Kidney biopsies that show that antibodies have been deposited along the glomeruli suggest that specialized cells of the immune system, called B and T cells, are causing damage to the kidneys through their increased activity. To suppress the action of B and T cells and to decrease the harmful deposits in the kidneys, drug treatments are required.\n* Patients with membranous nephropathy are often treated with immunosuppressive drugs such as cyclosporine or cytoxan plus steroids that attempt to reduce or suppress the activity of the immune system, decrease antibody production, and reduce antibody deposits in the kidney. However, not everyone responds to these medications and the kidney disease can return in some patients when the drugs are stopped. Also, there are side effects associated with long term usage of these medications. Rituximab, a different immunosuppressant, has also been used for this purpose. Although cyclosporine and Rituximab have been used separately, they have not been tried in combination as a possible treatment for membranous nephropathy.\n\nObjectives:\n\n\\- To determine the safety and effectiveness of combining rituximab and cyclosporine to treat membranous nephropathy.\n\nEligibility:\n\n\\- Individuals 18 years of age and older who have been diagnosed with membranous nephropathy based on a kidney biopsy done within the preceding 24 months, and who have had excess levels of protein in the urine for at least 6 months based on urine and blood tests.\n\nDesign:\n\n* Potential participants will be screened with an initial clinic evaluation and full medical history.\n* Before the treatment, there will be a run-in period that will last up to 2 months. During this time, participants will be placed on a blood pressure lowering medication and will not take any other immunosuppressant medications.\n* Participants will visit the NIH clinical center for a baseline evaluation, four intravenous infusions of rituximab, and also at 1- to 6-month intervals throughout the study.\n* Active treatment period will involve a 6-month course of cyclosporine and a total of four doses of rituximab. Participants will take cyclosporine tablets twice daily, and have two infusions of rituximab given 2 weeks apart, After 6 months, the cyclosporine dose will slowly be decreased over several weeks and then completely discontinued. Participants will then receive another course (two doses 2 weeks apart) of rituximab, depending on results of blood work.\n* Participants will have frequent blood and urine tests performed to monitor the results of treatment and reduce the chance of side effects.",[26,171,172,173,174],"Proteinuria","Autoimmune Disease","Glomerular Disease","Membranous Glomerulonephritis",[176,26,93,177,171],"Kidney Disease","Clinical Trial","2026-06-11",{"date":180,"type":42},"2026-06-12",{"date":182,"type":42},"2010-12-22",{"date":184,"type":20},"2027-12-31",{"name":48,"class":49},{"id":187,"slug":4,"hasResults":10,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":50},"100609456","NCT07214818","SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome","Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Adult Patients With Nephrotic Syndrome: A Randomized Controlled Trial","SGLT2-NS","Inclusion Criteria:\n\nAdult patients (≥18 years). Biopsy-confirmed primary nephrotic syndrome (e.g., idiopathic membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis).\n\nEstimated glomerular filtration rate (eGFR) ≥25 mL\u002Fmin\u002F1.73m² using CKD-EPI formula.\n\nOn stable dose of immunosuppressive therapy and renoprotective agents for ≥4 weeks prior to randomization.\n\nAble to signed informed consent.\n\nExclusion Criteria:\n\nDiagnosis of secondary nephrotic syndrome as : diabetes mellitus, lupus nephritis, and amyloidosis.\n\n* Impaired liver functions (ALT or AST values exceeding 3 folds upper limit of normal (ULN) at the screening visit).\n* Glomerular hematuria (red blood cells more than ten cells per high power field (HPF) after routine urinalysis for more than three times in the last 2 weeks).\n* History of severe hypersensitivity or contraindications to dapagliflozin or empagliflozine.\n* Pregnancy or breastfeeding.",{"count":194,"type":20},75,[23,196],"PHASE3","This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome. The study will compare three groups: dapagliflozin plus standard therapy, empagliflozin plus standard therapy, and standard therapy alone.\n\nThe primary objective is to assess whether SGLT2 inhibitors reduce proteinuria, maintain remission, and prevent relapse. Secondary objectives include evaluating effects on kidney function (eGFR, serum creatinine) and monitoring safety outcomes.\n\nParticipants will continue their baseline standard care and will be followed for 6 months with regular clinical evaluations, laboratory tests, and adverse event monitoring.",[26],[200,201,202,171,203],"SGLT2 inhibitors","Dapagliflozin","Empagliflozin","Primary Nephrotic Syndrome","2026-06-08",{"date":206,"type":42},"2026-06-09",{"date":208,"type":42},"2025-11-15",{"date":210,"type":20},"2026-09-06",{"name":212,"class":158},"Mansoura University",{"id":214,"slug":4,"hasResults":10,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":10,"sex":15,"minAge":219,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":4,"leadSponsor":232,"locationsCount":50},"100054889","NCT00001979","Immune System Related Kidney Disease","Studies of Immunologically-Mediated Kidney Diseases","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, a participant must meet all of the following criteria:\n\n1. Adults \\>= 18 years of age and children 10-17 years of age\n2. Participants with\n\n   1. known, proven, or suspected immunologically-mediated kidney diseases, including but not limited to nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with other systemic or connective tissue disorders, OR\n   2. immunologically-mediated diseases with the potential for kidney disease.\n3. Ability of the participant or guardian to understand and the willingness of the participant or guardian to provide written informed consent.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Concomitant medical problems which would confound the interpretation of studies of the immunologic kidney disorder.\n2. Concomitant medical, surgical, or other conditions for which inadequate facilities or funds are available to support their care at the NIH.","10 Years","99 Years",{"count":222,"type":20},2000,"Kidney diseases related to the immune system include, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with connective tissue disorders.\n\nThis study will allow researchers to admit and follow patients suffering from autoimmune diseases of the kidney. It will attempt to provide information about the causes and specific abnormalities associated with autoimmune kidney disease.\n\nPatients with kidney disease as a result of their immune system, and patients with diseases of the immune system who may later develop kidney disease, will be potential subjects for this study.\n\nPatients will undergo a history and physical examination, and standard laboratory test to more closely understand the causes, signs, symptoms, and responses to medication of these diseases. Based on these evaluations the patients may qualify as candidates for other experimental studies. At any time these patients may be asked to submit blood or urine samples for further research.",[176,26],[176,226,227],"Chronic Kidney Disease","Natural History","2026-06-05",{"date":204,"type":42},{"date":231,"type":42},"1992-06-25",{"name":48,"class":49},{"id":234,"slug":4,"hasResults":10,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":10,"sex":15,"minAge":239,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":21,"phases":243,"briefSummary":245,"conditions":246,"keywords":252,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":159},"100636151","NCT07561957","A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines","A Smart Phone Application to Improve Adoption of the 2024 KDIGO CKD Guidelines","Inclusion Criteria:\n\n* Adults aged ≥16 years.\n* Diagnosed with CKD stages 1-5.\n* Owns a smartphone and is capable of using mobile applications.\n* Provides informed consent.\n\nExclusion Criteria:\n\n* Inability to provide informed consent due to a neurocognitive impairment.\n* Age 30 years or older\n\nThe study will be conducted in the already established SJH Young Adult Clinic, with anticipated expansion coinciding with the co-location Children's Health Ireland (CHI) on site.","16 Years","30 Years",{"count":242,"type":20},80,[244],"NA","The goal of this study is to establish whether use of a digital intervention can improve adherence and alignment with the Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) 2024 Guidelines.\n\nA subset of the study will focus on whether the intervention improves outcomes for young adults living with CKD, in the context of the imminent co-location of Children's Health Ireland on the St. James's Hospital campus.\n\nYoung adults with CKD transitioning to adult services are recognised as a high-risk and vulnerable cohort, with many individuals unaware of increased cardiovascular risk and mortality¹². In response, and in the context of the co-location of Children's Health Ireland on the St. James's Hospital site, a young adult nephrology clinic has been established.\n\nThe KDIGO CKD 2024 Guidelines identify transition as a period of increased risk and include recommendations regarding cardiovascular risk factor targets and the use of therapies known to delay CKD progression³.\n\nElectronic communication is a preferred method for accessing health information among many young adults⁴⁵ and aligns with Sláintecare digital health strategies⁶. A recently established, award-winning St. James's Hospital renal smartphone application is currently used by over 3,000 individuals living with CKD.\n\nThe study aims to determine whether use of the application improves adherence to KDIGO guideline recommendations, with the objective of delaying CKD progression and associated complications. The application will support optimisation of care by signposting opportunities for evidence-based interventions (e.g., SGLT2 inhibitors, renin-angiotensin system inhibition) to healthcare providers. The application will also provide participants with tailored recommendations, reminders, educational materials, and collection of patient-reported outcome measures.\n\nDue to the diverse population and range of specialties at St. James's Hospital, the young adult clinic serves distinct subgroups, including individuals with sickle cell anaemia and survivors of cancer and haematological malignancies. These populations will be examined in the context of KDIGO guideline implementation, contributing to a limited international evidence base.\n\nThis research evaluates an intervention designed to improve care for adults living with chronic kidney disease.",[226,171,247,248,26,249,250,251],"Blood Pressure Control","Congenital Anomalies of the Kidneys and Urinary Tract","Sickle-Cell Nephropathy","Tuberous Sclerosis Complex","Cancer Survivors",[253,176,254,255],"Digital Interventions","Paediatric Nephrology","Transitional Nephrology","2026-04-24",{"date":258,"type":42},"2026-05-01",{"date":260,"type":42},"2026-01-14",{"date":262,"type":20},"2027-06-01",{"name":264,"class":158},"St. James's Hospital, Ireland",{"id":266,"slug":4,"hasResults":10,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":271,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":21,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":159},"100571333","NCT06718894","Multitarget Strategy for Primary Podocytopathies","PODO-TARGET","Inclusion Criteria:\n\n* Signature of informed consent for study participation\n* One of the following conditions:\n\n  1. Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) showing clinical and\u002For histological evidence of post-transplant recurrence.\n  2. Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) without clinical and\u002For histological evidence of post-transplant recurrence.\n  3. Patients with primary podocytopathies in their native kidneys in an active clinical phase of the disease.\n  4. Patients with podocytopathies presenting clinical features compatible with a secondary form due to another condition.\n  5. Patients with glomerulonephritis other than primary podocytopathies (e.g., IgA nephropathy, systemic lupus erythematosus, membranous nephropathy).\n  6. Patients with no history of renal diseases\n\nExclusion Criteria:\n\n* Subjects affected by primary podocytopathies or other glomerulonephritides in clinical remission or with ESRD (eGFR \\\u003C 15 ml\u002Fmin) and\u002For on renal replacement therapy\n* Individuals unable to understand and consent to the study procedures\n* Any clinical condition that, according to the investigator's judgment, could compromise patient safety during study participation",true,{"count":273,"type":20},150,[244],"The goal of this clinical trial is to verify whether a cell culture system can be used to evaluate the presence of a factor capable of causing proteinuria in the serum of patients with primary podocytopathies. This system will also be used to evaluate the in vitro efficacy of a combined therapy for the treatment of this disorder.\n\nResearchers will compare samples from patients with primary podocytopathies with those obtained from healthy subjects and patients with other renal disorders.\n\nParticipants will be asked to visit the clinic at regular intervals for up to 36 months, and to provide blood and urine samples (and a sample of the discarded plasmapheresis effluent in case the procedure is performed).",[26],[278,279],"podocytopathy","transplant","2026-03-25",{"date":282,"type":42},"2026-03-27",{"date":284,"type":42},"2025-06-19",{"date":286,"type":20},"2032-11",{"name":288,"class":158},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":290,"slug":4,"hasResults":10,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":10,"sex":15,"minAge":70,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":297,"conditions":298,"keywords":308,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":50},"100478094","NCT05505500","Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.","Preparing a Clinical Outcomes Assessment Set for Nephrotic Syndrome","Prepare-NS","Criteria for the Observer Reported Outcomes (ObsRO) cohort of the study:\n\nInclusion Criteria:\n\n1. Parents\u002Fguardians must be able to read and understand English;\n2. Parents\u002Fguardians must be caring for a child (ages 2-11.999) with a medically documented diagnosis of idiopathic (primary) Nephrotic Syndrome (NS) or primary or monogenic NS associated kidney disease. Populations with Primary NS Conditions: Focal segmental glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin M (IgM) Nephropathy, Membranous Nephropathy (MN), and childhood - onset nephrotic syndrome not biopsied;\n3. The child must have a current NS-associated edema\n4. The child must have native kidney function\n5. Parents\u002Fguardians must provide informed consent.\n\nExclusion Criteria:\n\n1\\. Index case with dialysis dependence throughout the 3-month pre-enrollment period\n\nCriteria for the Patient Reported Outcomes (PRO) cohort of the study:\n\nInclusion Criteria:\n\n1. ≥8 years of age\n2. Able to read and understand English\n3. Primary (idiopathic) kidney disease that causes NS or monogenic NS associated kidney disease.\n\n   i. Populations with Primary Nephrotic Syndrome (NS) Conditions include: FSGS, MCD, IgM nephropathy, MN, and childhood - onset nephrotic syndrome not biopsied\n4. Current NS-associated edema\n5. Kidney function with most recent estimated Glomerular Filtration Rate (eGFR) \\> 25 ml\u002Fmin\u002F1.73m2\n6. Informed Consent: For patients ≥8 to \\\u003C18 years of age: a parent or legal guardian provide informed consent and the patient must provide assent. Patients ≥18 years of age must provide informed consent.\n\nExclusion Criteria:\n\n1. Native kidney disease participant with dialysis dependence during the 3-month pre-enrollment period\n2. Co-existing significant chronic or severe acute health condition that has the potential to influence how the participant feels or functions as related to fluid overload in NS",{"count":273,"type":20},"Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome. Interviews with patients (child and adult) and parents of young children will be conducted. The information collected from the interviews will be used to develop a survey to use when testing new medications for Nephrotic Syndrome.\n\nPlease consider participating in a 1-hour long interview with the Prepare-NS research study to discuss children and adults experiences with swelling.",[299,300,301,121,302,303,304,26,173,305,306,307,79],"Fluid Overload","Glomerulosclerosis, Focal Segmental","Edema","Minimal Change Disease","Minimal Change Nephrotic Syndrome","IgM Nephropathy","Nephrotic Syndrome, Minimal Change","Nephrotic Syndrome in Children","Nephrotic Syndrome With Edema (Diagnosis)",[26,309,310,299,301,79,302,121,304],"Child","Adult","2025-12-15",{"date":313,"type":42},"2025-12-22",{"date":315,"type":42},"2022-04-18",{"date":317,"type":20},"2026-04-30",{"name":319,"class":158},"University of Michigan",{"id":321,"slug":4,"hasResults":10,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":21,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":50},"100420785","NCT04759274","Diuretic Tuner Clinical Decision Support","Diuretic Tuner Clinical Decision Support Mobile Device Application for Diuretic Titration in Hypervolemic States","Inclusion Criteria:\n\n* The presence of nephrotic range proteinuria (\\> 3 g\u002Fd proteinuria by 24hr urine protein, 24hr urine albumin, spot urine protein\u002Fcreatinine ratio, or spot urine albumin\u002Fcreatinine ratio) or stage 4 or 5 chronic kidney disease (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2 by Modification of Diet in Renal Disease equation) PLUS\n* Clinical signs of hypervolemia present (lower extremity edema, ascites, or pleural effusions) with an estimated dry weight (defined as edema-free weight without orthostatic hypotension) 5 lbs less than enrollment body weight\n\nExclusion Criteria:\n\n* Weight \\\u003C 100 lbs or \\> 300 lbs.\n* Autonomic insufficiency resulting in orthostatic hypotension at screening\n* Hypokalemia at enrollment (defined as serum potassium \\\u003C 3.5 mmol\u002FL)\n* Moderate to severe hyponatremia at enrollment (defined as serum sodium \\\u003C 130 mmol\u002FL)\n* Serum creatinine \\> 6 mg\u002FdL or \\> 1.5 times baseline\n* Patients who are unable or unwilling to measure their home blood pressures and weights\n* Patients without a working phone number and smart phone device\n* Expectation that the patient will require dialysis initiation within \\\u003C 3 months\n* Expected lifespan of \\\u003C 6 months\n* The presence of a medical condition that would interfere with effectively using the Diuretic Tuner (dementia, illiteracy, or blindness)\n* Pregnant patients\n* Prisoners",{"count":167,"type":20},[244],"This purpose of this study is to determine the effectiveness of a mobile phone application in helping to control body swelling in patients with kidney problems. The application will help in the day to day adjustments in diuretic medication dosing.\n\nParticipants in this study will have an application loaded on to their mobile phone by the study team and be taught how to use it over a 2 hour visit. Participants will need to check their blood pressure and weight daily and enter this information into the mobile phone application every day. Participants will need to follow daily instructions in their medication dosing provided by the application. There will be periodic blood testing. This will happen at 2 weeks, 90 days, and up to 4 other times if necessary. At the end of the study there is a 2 hour study visit during which participants will answer a survey. The total length of the study is 90 days.",[301,330,331,26],"Hypervolemia","Chronic Kidney Diseases","2025-09-14",{"date":334,"type":42},"2025-09-16",{"date":336,"type":42},"2023-11-20",{"date":338,"type":20},"2026-08",{"name":340,"class":158},"University of Texas Southwestern Medical Center",{"id":342,"slug":4,"hasResults":10,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":50},"100544824","NCT06373913","The Role of Proprotein-convertase-subtilisin\u002FKexin-type 9 in Kidney Damage in Nephrotic Syndrom","PCSK9","Inclusion Criteria:\n\n* 18 years old\n* Patients admitted to the Medical Department and\u002For the Medical Emergency Department, Kolding Sygehus.\n\nExclusion Criteria:\n\n* Refusal to give informed consent\n* Treatment with PCSK9 inhibitors\n* Any acute or chronic condition that would limit the ability of the patient to participate in the study\n* Control group: proteinuria",{"count":194,"type":20},"Nephrotic syndrome (NS) is characterized by gross proteinuria (\\>3.5 g\u002Fday), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality.\n\nThe study aim is to investigate the role of the protein convertase subtilisin\u002Fkexin type 9 (PCSK9) in hyperlipidemia of NS, which has been suggested to play an important role. This is done by testing the following hypotheses:\n\n1. PCSK9 is increased in patients with NS and hyperlipidemia compared to kidney-healthy controls\n2. The level of PCSK9 in plasma correlates to the degree of proteinuria.\n3. PCSK9 i increased in the kidney tissue of patients with NS\n\nThe study will compare plasma levels of PCSK9 in correlation with degree of protein in the urine between test persons with NS and kidney healthy controls. Furthermore the investigators will study the the degree of PCSK9 in the kidney in biopsies obtained from test persons with nephrotic syndrome and test persons without proteinuria.",[350,26],"Hyperlipidemias","2025-09-02",{"date":353,"type":42},"2025-09-09",{"date":355,"type":42},"2023-06-01",{"date":357,"type":20},"2028-07-30",{"name":359,"class":158},"Kolding Sygehus",{"id":361,"slug":4,"hasResults":10,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":367,"conditions":368,"keywords":369,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":50},"100541809","NCT06334692","Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome","BLINDER","Inclusion Criteria:\n\n* Adult (\\>18 years) males and females\n* Patients with biopsy-proven idiopathic MCD or FSGS (cases)\n* Patients with biopsy-proven idiopathic membranous nephropathy (controls)\n* Patients who provided consent to store their samples in the certified CRB biobank\n\nExclusion Criteria:\n\n* Reasonable possibility of a secondary cause of NS (for cases) or MN (for controls) at time of blood collections\n* Active viral or bacterial infections at time of blood collections",{"count":19,"type":20},"This retrospective study is aimed at evaluating the levels of circulating anti-nephrin autoantibodies in patients with INS, including those with MCD\u002FFSGS and in patients who have experienced relapse of FSGS post-transplant, compared to those of a control group of patients with nephrotic syndrome due to primary membranous nephropathy (MN).",[26],[370,371,372,373,374,375],"Idiopathic nephrotic syndrome","Minimal change disease","Focal segmental glomerulosclerosis","Permeability factor(s)","B cells","Nephrin autoantibodies","2025-08-27",{"date":378,"type":42},"2025-09-04",{"date":380,"type":42},"2024-03-19",{"date":382,"type":20},"2028-03",{"name":384,"class":158},"Mario Negri Institute for Pharmacological Research",{"id":386,"slug":4,"hasResults":10,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":271,"sex":15,"minAge":16,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":21,"phases":394,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":4},"100601879","NCT07116239","Edoxaban Steady-State PK\u002FPD in Adults With Nephrotic Syndrome","Steady-state Pharmacokinetics and Pharmacodynamics of Edoxaban in Adults With Nephrotic Syndrome: A Non-randomized Open-label, Parallel Arm and Single-center Study","Inclusion Criteria:\n\n1. Nephrotic syndrome Group:\n\n   * Age between 18-70 years old\n   * Diagnosed with nephrotic syndrome: proteinuria≥3.5 g\u002F24h or morning urine protein\u002Fcreatinine ratio ≥3.0g\u002Fg), with serum albumin \\\u003C30g\u002FL present at the time of enrollment, with or without edema or hyperlipidemia\n   * Calculated creatinine clearance (CrCl) \\>50ml\u002Fmin using the Cockcroft-Gault formula\n   * Actual body weight \\>60kg, and body mass index within the range of 18.5-28kg\u002Fm2\n   * Signed informed consent form\n2. Healthy volunteer Group:\n\n   * Age between 18-70 years old\n   * Serum albumin ≥40g\u002FL\n   * Calculated CrCl \\>50ml\u002Fmin using the Cockcroft-Gault formula\n   * Actual body weight \\>60kg, and body mass index within the range of 18.5-28kg\u002Fm2\n   * Signed informed consent form\n\nExclusion Criteria:\n\n* Serun albumin \\\u003C30 g\u002FL for other reasons in patients with nephrotic syndrome as judged by the investigator\n* Prolonged PT, INR, APTT at baseline (defined as greater than the upper limit of normal values)\n* Platelet count \\\u003C100×109\u002FL or ≥300×109\u002FL due to hematological diseases confirmed by laboratory tests\n* History of: gastrointestinal bleeding, intracranial hemorrhage, hemoptysis, or other clinically documented bleeding from internal organs within the last 3 months; surgery (except \\>3 days after renal biopsy without bleeding complications) or trauma. Bleeding complications after renal biopsy are defined as: ① bleeding (hematuria, perirenal hematoma, or arteriovenous fistula) that occur after renal biopsy requiring transfusion, resulting in altered hemodynamics, or requiring surgery or interventional treatment; ② symptomatic perirenal hematoma; and ③visible hematuria that persist for \\>3 days postoperatively.\n* A lesion or condition with a significant risk of major bleeding, such as current or recent gastrointestinal ulcer, malignant tumors with a high risk of bleeding, esophageal varices, arteriovenous malformations, vascular aneurysms, or major intravertebral or intracerebral vascular malformations.\n* Serious bleeding disorders as judged by the investigator\n* Systemic lupus erythematosus with or without renal damage\n* Bleeding or thrombophilia disorders as judged by the investigator\n* History of stroke\n* History of congestive heart failure (New York grade II or above) at the time of screening\n* Liver dysfunction (cirrhosis or bilirubin \\>2×, and serum transaminases \\>3×, upper limit of normal)\n* Use of (but not limited to) the prescription medications that are inhibitors or inducers of CYP3A4 and\u002For P-gp within the past 14 days:\n\n  * CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, etc.) ②CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, etc.)\n\n    * P-gp inducers (e.g., apalutamide, rifampicin, etc.) ④ P-gp inhibitors (e.g., dronedarone, cyclosporine, erythromycin, ketoconazole, quinidine, verapamil, amiodarone, etc.) ⑤Selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)\n* Use of antiplatelet and\u002F or anticoagulant agents within 5 half-lives (at least 7 days): including but not limited to heparin, heparin derivatives, aspirin, clopidogrel, prasugrel, nonsteroidal anti-inflammatory drugs, warfarin, rivaroxaban, dabigatran, apixaban, etc.\n* Pregnant or breastfeeding women or women of childbearing age without contraception\n* Uncontrolled severe hypertension (SBP≥180mmHg, DBP≥110mmHg)\n* Conditions considered unsuitable for inclusion in this study, judged by investigator\n* Patients with hypersensitivity to the active ingredient or other excipients of the Edoxaban and enoxaparin sodium\n* History of immune-mediated heparin-induced thrombocytopenia (HIT) or presence of circulating antibodies within the previous 100 days.\n* Spinal or epidural anesthesia or local anesthesia within 24 hours prior to the administration of enoxaparin sodium and Edoxaban","70 Years",{"count":393,"type":20},60,[244],"A study to evaluate the impact of nephrotic syndrome on the steady state pharmacokinetics and pharmacodynamics of edoxaban compared to health volunteers, and whether edoxaban can provide an equivalent anticoagulant effect to enoxaparin sodium.",[26,397],"Hypoalbuminemia",[399,123,400,401],"edoxaban","hypoalbuminemia","enoxaparin","2025-08-04",{"date":404,"type":42},"2025-08-11",{"date":406,"type":20},"2025-09",{"date":408,"type":20},"2026-02",{"name":410,"class":158},"Peking University People's Hospital",{"id":412,"slug":4,"hasResults":10,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":271,"sex":15,"minAge":70,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":21,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":50},"100563957","NCT06622915","Cardiac Performance Evaluation in Children With Steroid Dependent vs Steroid Resistant Nephrotic Syndrome","Inclusion Criteria:\n\n* Children with primary nephrotic syndrome.\n\n  * Age: 2 - 14 years.\n  * Both males and females\n\nExclusion Criteria:\n\n* Patients of primary cardiac diseases (e.g., congenital or rheumatic heart disease, cardio- myopathy).\n\nPatients who refuse to give written informed consent to study","14 Years",{"count":393,"type":20},[244],"nephrotic syndrome (NS) is one of the most common pediatric kidney diseases There is an increased incidence of heart disease in patients with primary nephrotic syndrome (PNS) compared to the normal population Conventional Echocardiography is usually utilized to diagnose myocardial dysfunction. Tissue Doppler imaging is a non-invasive cardiac imaging technique which measures the velocity of the longitudinal motion of the mitral annulus, tricuspid annulus and the basal part of interventricular septum",[26],"2024-10-01",{"date":423,"type":42},"2024-10-02",{"date":425,"type":42},"2024-07-15",{"date":427,"type":20},"2025-07-15",{"name":429,"class":158},"Sohag University",{"id":431,"slug":4,"hasResults":10,"nctId":432,"briefTitle":433,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":10,"sex":15,"minAge":435,"maxAge":16,"enrollmentInfo":436,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":50},"100556814","NCT06530004","Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children","Inclusion Criteria:\n\n* Children clinically diagnosed with FRNS\u002FSDNS\u002FSRNS with complete clinical data;\n* age \\\u003C 18 years old;\n* For the first time using RTX treatment, and used in nephrotic syndrome ease;\n* The follow-up for 1 year or more.\n\nExclusion Criteria:\n\n* Congenital or infantile nephrotic syndrome, secondary nephrotic syndrome (such as lupus nephritis, IgA nephropathy, purpura nephritis, hepatitis B nephritis, etc.);\n* Active stage of hepatitis, complicated with severe infection, severe deficiency of immune response, malignant diseases;\n* Estimated glomerular filtration rate (GFR) \\\u003C60mL\u002Fmin\u002F1.73m2.","1 Year",{"count":437,"type":20},50,"This was a retrospective study. Children who were diagnosed with refractory nephrotic syndrome and treated with rituximab (RTX) and followed up for ≥1 year in the Department of Pediatrics, the First Affiliated Hospital of Xiamen University from March 2020 to March 2026 were enrolled. Personal information, past medical history, clinical examination data and follow-up data before and after the use of RTX were extracted from the medical record system. (1) The median relapse-free survival, the number of relapses and the adverse reactions of RTX were compared before and after RTX treatment, and the clinical efficacy and safety of RTX were evaluated. (2) By comparing the annual relapse frequency, reduction and withdrawal of steroids and immunosuppressive agents, B cell reconstitution and adverse drug reactions between prophylactic RTX and post-relapse RTX maintenance regimens; (3) Multivariate analysis of risk factors for recurrence of nephropathy after RTX treatment. (4) growth indicators monitoring patient evaluation and RTX medical economic benefit analysis.",[26,440,441,442],"Rituximab","Children","Efficacy","2024-07-29",{"date":445,"type":42},"2024-07-31",{"date":447,"type":42},"2020-03-01",{"date":449,"type":20},"2028-03-01",{"name":451,"class":158},"The First Affiliated Hospital of Xiamen University",{"id":453,"slug":4,"hasResults":10,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":461,"conditions":462,"keywords":465,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":50},"100550127","NCT06443034","Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1","Predictive Determinants of Nephrotic Syndrome Remission in Patients With Focal Segmental Glomerulosclerosis or Minimal Change Disease and At-risk Polymorphism of APOL1 Gene","NEPHROL1","Inclusion Criteria:\n\n* Adult patients followed in 6 nephrology centers between 01\u002F01\u002F2016 and 01\u002F06\u002F2024.\n* With characterization of APOL1 gene risk status\n* Proteinuria\u002Fcreatinuria ratio \\> 3 g\u002Fg at diagnosis of renal disease (within 48 hours of the diagnostic renal biopsy)\n* Hypoalbuminemia \\\u003C 30 g\u002FL at diagnosis of renal disease (within 48 h of diagnostic renal biopsy)\n* Minimal change disease or segmental and focal hyalinosis lesions on renal biopsy.\n\nExclusion Criteria:\n\n* Presence of diffuse deposits of immunoglobulins or complement fractions on immunofluorescence study\n* Presence of endo- or extracapillary hypercellular lesions on light microscopy\n* Opposition to the use of medical data",{"count":460,"type":20},124,"This is a multicentric retrospective observational cohort study.\n\nAs primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal change disease or focal segmental glomerulosclerosis, and an at-risk variant of the APOL1 gene.\n\nAs secondary objectives, this study aims:\n\n* To evaluate the benefit of corticosteroids in obtaining the remission of nephrotic syndrome\n* To identify the predictors of complete renal remission of nephrotic syndrome\n* To evaluate the benefit of corticosteroids in reducing the incidence of end-stage renal disease\n* To assess the adverse events of corticosteroids in patients treated with corticosteroids.",[26,463,464],"Focal Segmental Glomerulosclerosis","APOL1 Associated Kidney Disease",[466,467,468,469,372,371],"Nephrotic syndrome","Covid-19 associated nephropathy","human immunodeficiency virus associated nephropathy","APOL1 associated kidney disease","2024-06-03",{"date":472,"type":42},"2024-06-05",{"date":474,"type":20},"2024-06-30",{"date":476,"type":20},"2024-12-30",{"name":478,"class":158},"Assistance Publique - Hôpitaux de Paris",{"id":480,"slug":4,"hasResults":10,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":115,"enrollmentInfo":485,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":487,"conditions":488,"keywords":489,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":50},"100528509","NCT06161701","Steroid Diabetes in Patients With Kidney Disease","A Study on the Influencing Factors of Glucocorticoid Induced Elevated Blood Glucose in Nephrotic Patients","Inclusion Criteria:\n\n1. Patients who need to use glucocorticoids due to the following diseases: nephrotic syndrome, Immunoglobulin A nephropathy, membranous nephropathy, Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus；\n2. Initial daily dose of glucocorticoids greater than or equal to 10mg of prednisolone；\n\nExclusion Criteria:\n\n1. Patients with diabetes；\n2. Those who are unable to communicate through language；\n3. Uremic patients；\n4. Unable to perform blood glucose monitoring and follow-up as required；\n5. Those who have used glucocorticoids within the past 3 months and have accumulated a dose of 10mg or more of prednisone；\n6. Participated in other clinical studies。",{"count":486,"type":20},300,"If steroid diabetes is not recognized in time, it will cause irreversible damage to the body. Nephropathy patients are more likely to have steroid diabetes ,the incidence rate up to 25%,due to hypoalbuminemia, high-dose hormone and other reasons, so they need to be closely followed up, identified and intervened in time.",[26],[490],"steroid diabetes","2024-04-25",{"date":493,"type":42},"2024-04-29",{"date":495,"type":42},"2024-01-10",{"date":497,"type":20},"2027-02-28",{"name":499,"class":158},"Zhejiang Provincial People's Hospital",{"id":501,"slug":4,"hasResults":10,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":506,"targetDuration":219,"studyType":147,"phases":4,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":4},"100540335","NCT06315504","Circulating Factors in Nephrotic Syndrome","Circulating Factors in Nephrotic Syndrome - A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Plasma albumin \\\u003C 36 g\u002FL\n* Urine protein \\>3.5 g\u002Fday or urine protein\u002Fcreatinine-ratio (UPCR) \\> 3.5 or urine albumin\u002Fcreatinine-ratio (UACR) \\>2200 mg\u002Fg\n* Planned kidney biopsy\n* Able to give written informed consent\n\nExclusion Criteria:\n\n* Kidney transplant recipient\n* Previously undergone a kidney biopsy\n* Unable to understand written information in Danish",{"count":507,"type":20},104,"A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.",[26,121,302,510],"Primary Focal Segmental Glomerulosclerosis","2024-03-16",{"date":380,"type":42},{"date":514,"type":20},"2024-04-01",{"date":516,"type":20},"2034-04-01",{"name":518,"class":158},"Iain Bressendorff",{"id":520,"slug":4,"hasResults":10,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":10,"sex":15,"minAge":524,"maxAge":525,"enrollmentInfo":526,"targetDuration":4,"studyType":21,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":50},"100541072","NCT06325098","Implementation of a Diagnostic Workflow for Personalized Diagnosis of Nephrotic Syndrome","Inclusion Criteria:\n\n* Clinical diagnosis of NS (SSNS, SRNS, or NS relapsed after transplantation regardless of initial response to steroid therapy)\n* Age below 40 years at disease onset\n* Availability of clinical information\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Age at onset above 40 years\n* Kidney biopsy proving lesions other than FSGS and MCD","1 Month","40 Years",{"count":273,"type":20},[244],"Nephrotic syndrome (NS) is a clinical picture common to several diseases resulting from damage to podocytes and glomerular filtration barrier. Currently, there is limited consensus regarding the diagnostic pathway and management of the specific etiology. Some patients show complete response to first-line steroid therapy (steroid-sensitive nephrotic syndrome, SSNS), especially in children and young adults. The prognosis of this group is generally favorable. In contrast, patients unresponsive to steroids (steroid-resistant NS, SRNS) frequently undergo immunosuppressive therapies, which are burdened with numerous side effects. Resistance to treatment is associated with a high likelihood of progression to chronic renal disease (CKD) and kidney failure (ESKD). Recent evidence suggests that immunological mechanisms (including permeabilizing factors) are involved in the pathogenesis of post-transplant NS recurrence and SSNS.\n\nProviding patients with NS with a correct diagnosis is the cornerstone of personalized medicine, reducing morbidity and side effects of therapies, ensuring their appropriate prescription, and slowing or preventing progression to ESKD.",[26],"2024-03-15",{"date":532,"type":42},"2024-03-22",{"date":534,"type":42},"2022-01-26",{"date":536,"type":20},"2026-06-30",{"name":538,"class":158},"Meyer Children's Hospital IRCCS",{"id":540,"slug":4,"hasResults":10,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":115,"enrollmentInfo":544,"targetDuration":219,"studyType":147,"phases":4,"briefSummary":545,"conditions":546,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":50},"100528574","NCT06162546","ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank","Inclusion Criteria:\n\n* Resistant to standard Immunosuppressive agents (if clinically indicated, e.g. primary\u002Fnon-genetic forms)\n* Persistent urinary protein-to-creatinine (UP\u002FC) ratio \\>1.0 g\u002Fg\n* eGFR \\> 30 ml\u002Fmin per 1.73 m2\n* biopsy or a disease-causing genetic mutation associated with nephrotic syndrome\n\nExclusion Criteria:\n\n* Inability or unwillingness to comply with repeated assessments\n* Objections against participation at discretion of the investigator\n* Secondary\n* Patients with steroid-dependence\u002Ffrequently relapsing disease (but achievement of complete remission)",{"count":19,"type":20},"Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, fluid retention and impaired renal function.\n\nThe AustRian RESistanT NEPHROtic Syndrome Treatment Response RegIStry and Biobank (ARREST-NEPHROSIS) sets out to achieve the following goals, as typical categories of rare disease registries\n\n1. Obtaining real world data on practice patterns and outcomes\n2. Networking between affected patients, families, and clinicians.\n3. Establish a patient base for facilitated recruitment in studies of drugs, medical devices, and products\n4. Development of a Biobank to enable research of potential biomarkers and therapy or disease courses",[463,171,26,547],"Nephrotic Syndrome Steroid-Resistant","2023-11-30",{"date":550,"type":42},"2023-12-08",{"date":552,"type":42},"2023-01-01",{"date":554,"type":20},"2033-12-31",{"name":556,"class":158},"Christoph Aufricht",{"id":558,"slug":4,"hasResults":10,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":21,"phases":565,"briefSummary":566,"conditions":567,"keywords":568,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":50},"100494338","NCT05716880","Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome","FORMA - a Multicenter Randomized-controlled Trial to Evaluate the Efficacy and Safety of Ketoanalogues of Essential Amino Acids in Prophylaxis of Protein-energy Wasting in Nephrotic Syndrome","FORMA","Inclusion Criteria:\n\n* Nephrotic syndrome with serum albumin \\\u003C 3.0 g\u002FdL and daily proteinuria of \\> 3.5 g\u002Fday or \\> 50 mg\u002Fkg;\n* New diagnosis or relapse of nephrotic syndrome (defined as: proteinuria of \\\u003C 2.0 g\u002Fday or uPCR \\\u003C 2000 mg\u002Fg in the last 6 months prior to relapse and prednison dose equal to or less than 10 mg\u002Fday in the last 3 months prior relapse);\n* Glomerular filtration rate qual to or higher than 30 mL\u002Fmin\u002F1.73m2 based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n\nExclusion Criteria:\n\n* Diabetic kidney disease;\n* Small vessels vasculitis;\n* Systemic lupus erythematosus;\n* Positive antinuclear antibodies, anti-dsDNA or antineutrophil cytoplasmic antibodies (ANCA);\n* Positive anti-HIV or anti-hepatitis C antibodies, HBsAg;\n* HbA1c \\>7%;\n* Monoclonal gammopathy;\n* Pregnancy;\n* Body mass index \\>= 40 kg\u002Fm2;\n* Severe acute or chronic disease affecting nutritional status;\n* Neoplasm;\n* Contraindication to Ketosteril;\n* Alcohol or drug abuse;\n* Mental disorders;\n* Failure to comply with medical recommendations, lack of cooperation;\n* Participation in other clinical trial or the use of Ketosteril in the last 1 year prior to screening.",{"count":273,"type":20},[196],"The goal of this non-commercial clinical trial is to assess efficacy and safety of ketoanalogues of essential amino acids in the prevention of protein-energy wasting in nephrotic syndrome.",[26],[123,569,570,571,572,573],"protein-energy wasting","neph-PEW","lean tissue mass","Ketosteril","ketoanalogues","2023-01-30",{"date":576,"type":42},"2023-02-08",{"date":578,"type":42},"2023-01-03",{"date":580,"type":20},"2027-08-31",{"name":582,"class":158},"Military Institute od Medicine National Research Institute",{"id":584,"slug":4,"hasResults":10,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":10,"sex":15,"minAge":590,"maxAge":16,"enrollmentInfo":591,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":593,"conditions":594,"keywords":595,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":609},"100179059","NCT01605266","INSIGHT (Insight Into Nephrotic Syndrome)","INSIGHT (Insight Into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics)","INSIGHT","Inclusion Criteria:\n\n1. diagnosis of nephrotic syndrome\n2. signed informed consent and assent appropriate for age\n3. ages 6 months -18 years old and\n4. ability to complete questionnaires\n\nExclusion Criteria:\n\n1. congenital nephrotic syndrome (less than age 1)\n2. syndromic disease with multiple organ involvement\n3. inability to provide consent by primary care providers\n4. conditions such as systemic lupus erythematous.","6 Months",{"count":592,"type":20},1000,"INSIGHT is a longitudinal study of childhood nephrotic syndrome to determine genetic, serologic and environmental factors contributing to nephrotic syndrome and disease progression.",[26],[596,597,598,599,123],"pediatric","kidney disease","minimal change disease","focal segmental glomerulosclerosis","2022-10-24",{"date":602,"type":42},"2022-10-25",{"date":604,"type":4},"2011-01",{"date":606,"type":20},"2032-01",{"name":608,"class":158},"The Hospital for Sick Children",4,{"id":611,"slug":4,"hasResults":10,"nctId":612,"briefTitle":613,"officialTitle":613,"acronym":4,"eligibilityCriteria":614,"healthyVolunteers":10,"sex":15,"minAge":416,"maxAge":4,"enrollmentInfo":615,"targetDuration":219,"studyType":147,"phases":4,"briefSummary":617,"conditions":618,"keywords":619,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":50},"100285922","NCT03001934","Super Chinese Nephrotic Syndrome Registration System (SUCCESS)","Inclusion Criteria:\n\n* Nephrotic syndrome patients regardless of the primary causes\n\nExclusion Criteria:\n\n* No",{"count":616,"type":20},5000,"The investigators are registering all nephrotic syndrome (NS) patients regardless of the primary causes and developing a NS database in China. Patients will be followed-up and both baseline and follow-up information will be recorded in the registration system. The treatment response, longitudinal changes of renal function, renal survival, patient survival, infection events and acute kidney injury etc, will be analyzed using the NS database.",[26],[466,620,621],"Treatment response","Renal function","2020-10-20",{"date":624,"type":42},"2020-10-22",{"date":626,"type":4},"2016-04",{"date":628,"type":20},"2028-12",{"name":630,"class":158},"Sun Yat-sen University",""]